Savara Amends Loan Agreement, Securing Up to $75M Additional Financing Contingent on MOLBREEVI FDA Approval

summarizeSummary

Savara Inc. amended its loan agreement to secure up to $75 million in additional term loans, contingent on FDA approval of its MOLBREEVI product, and extended key financial covenant compliance dates.

check_boxKey Events

• Secures Additional Term Loans

  The company amended its loan agreement to provide for up to an aggregate of $105 million in term loans, with $75 million of additional funds now available.

• FDA Approval Contingency

  The ability to draw the additional $75 million is contingent upon FDA approval of MOLBREEVI for the treatment of aPAP, directly linking financing to a major product milestone.

• Extended Financial Covenants

  Compliance dates for the unrestricted cash requirement and the minimum trailing six-month revenue covenant have been extended to April 1, 2027, and September 30, 2027, respectively.

• Intellectual Property as Collateral

  The amendment grants lenders a first-priority perfected security interest in the company's intellectual property.

auto_awesomeAnalysis

Savara Inc. has significantly bolstered its financial flexibility by amending its loan agreement with Hercules Capital, Inc., making up to an additional $75 million in term loans available. This capital is strategically tied to the anticipated FDA approval of its key product candidate, MOLBREEVI, for aPAP, following the positive Phase 3 results announced earlier this month. The amendment also extends compliance dates for critical financial covenants, providing the company with a longer runway and reduced near-term financial pressure. This move demonstrates lender confidence in MOLBREEVI's potential and provides crucial funding for potential commercialization or further development post-approval.